Ly Vu

Has grant

Assistant Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ly Vu is an Assistant Professor at the University of British Columbia, Canada. His research focuses on the intricate relationships between RNA modifications, immune evasion in cancer, and the role of RNA binding proteins in hematological malignancies. Recent publications include studies on RNA sequencing techniques, therapeutic strategies for cancer, and key molecular interactions in leukemia.

Recent Grants

Grant: Close

Uncovering the role of RNA-binding protein Syncrip in acute myeloid leukemia (AML)

Open Date: 2014-07-01

Close Date: 2018-07-01

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Julie Roda

Director, Head of Translational Sciences

UNITED STATES

View details

Alexendar Perez

University of California, San Francisco

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ly Vu

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (14)

Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features.

The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.

Emerging interactions between RNA methylation and chromatin architecture.

mRNA-based therapeutic strategies for cancer treatment.

Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesis.

RNA deadenylation complexes in development and diseases.

A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma.

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells.

RNA modifications in hematological malignancies.

miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells.

m6A RNA modifications: Key regulators of normal and malignant hematopoiesis.

Transcriptional control of CBX5 by the RNA binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia.

Introductions to the Community: Early-Career Researchers in the Time of COVID-19.

HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells.

Collaborators (2)

Julie Roda

Alexendar Perez

Make your next move.